Literature DB >> 9237501

On the many faces of Leber hereditary optic neuropathy.

R J Oostra1, N T Tijmes, J M Cobben, P A Bolhuis, B P van Nesselrooij, W A Houtman, M M de Kok-Nazaruk, E M Bleeker-Wagemakers.   

Abstract

Leber hereditary optic neuropathy (LHON) is a maternally inherited disorder, associated with mutations in the mitochondrial DNA, which is notorious for its aspecific presentations. Two pedigrees are described with cases that are atypical for LHON with respect to sex, age of onset, interval between the eyes becoming affected, course of the disease, concomitant disorders, additional test results, final visual acuity, and/or results of mtDNA analysis. Moreover, the pedigrees themselves did not suggest maternal inheritance. We analysed the diagnostic and clinical genetic difficulties related to the atypical aspects of these pedigrees. We conclude that mtDNA analysis is justified in every case of optic nerve atrophy with no clear cause. Identification of one of the three LHON specifically associated mtDNA mutations is essential to confirm the diagnosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9237501     DOI: 10.1111/j.1399-0004.1997.tb02496.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  3 in total

1.  Leber's hereditary optic neuropathy and vitamin B12 deficiency.

Authors:  Jan Willem R Pott; Kwok H Wong
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-08       Impact factor: 3.117

2.  Visual prognosis better in eyes with less severe reduction of visual acuity one year after onset of Leber hereditary optic neuropathy caused by the 11,778 mutation.

Authors:  Yukihiko Mashima; Kazuteru Kigasawa; Kei Shinoda; Masato Wakakura; Yoshihisa Oguchi
Journal:  BMC Ophthalmol       Date:  2017-10-18       Impact factor: 2.209

3.  Prognostic factors for visual acuity in patients with Leber's hereditary optic neuropathy after rAAV2-ND4 gene therapy.

Authors:  Yong Zhang; Xin Li; Jiajia Yuan; Zhen Tian; Hongli Liu; Dan Wang; Bin Li
Journal:  Clin Exp Ophthalmol       Date:  2019-05-08       Impact factor: 4.207

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.